Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H S Rasmussen

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Archives of Internal Medicine|May 1, 1989
Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled studyH S Rasmussen, P Aurup, K Goldstein, et al.
BMJ (Clinical Research Ed.)|September 4, 1993
Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarctionA M Galløe, H S Rasmussen, L N Jørgensen, et al.
British Journal of Clinical Pharmacology|October 1, 1991
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteersJ D Gemmill, C A Howie, P A Meredith, et al.
Liver|December 1, 1987
Differential diagnosis of jaundice: junior staff experience with the Copenhagen pocket chartA Malchow-Møller, L Mindeholm, H S Rasmussen, et al.
The American Journal of Cardiology|November 15, 1995
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study GroupY Bashir, P E Thomsen, J H Kingma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancerS Wojtowicz-Praga, J Torri, M Johnson, et al.
Gene Therapy|June 23, 2006
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatmentD J Stewart, J D Hilton, J M O Arnold, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Archives of Internal Medicine|May 1, 1989
Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled studyH S Rasmussen, P Aurup, K Goldstein, et al.
BMJ (Clinical Research Ed.)|September 4, 1993
Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarctionA M Galløe, H S Rasmussen, L N Jørgensen, et al.
British Journal of Clinical Pharmacology|October 1, 1991
A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteersJ D Gemmill, C A Howie, P A Meredith, et al.
Liver|December 1, 1987
Differential diagnosis of jaundice: junior staff experience with the Copenhagen pocket chartA Malchow-Møller, L Mindeholm, H S Rasmussen, et al.
The American Journal of Cardiology|November 15, 1995
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study GroupY Bashir, P E Thomsen, J H Kingma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancerS Wojtowicz-Praga, J Torri, M Johnson, et al.
Gene Therapy|June 23, 2006
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatmentD J Stewart, J D Hilton, J M O Arnold, et al.
Pageof 4